2024
Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009)
Beiner M, Powell L, Rogula B, Potashman M, Wirtz V, Schmahmann J, Perlman S, Coric V, L’Italien G. Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia (S35.009). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205167.Peer-Reviewed Original ResearchNatural history cohortMatching-adjusted indirect comparison
2021
Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
Popoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, Coric V, L’Italien G, Moren J. Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine. Headache The Journal Of Head And Face Pain 2021, 61: 906-915. PMID: 34021585, PMCID: PMC8361942, DOI: 10.1111/head.14128.Peer-Reviewed Original ResearchConceptsMonthly migraine daysMatching-adjusted indirect comparisonHealth-related qualityEVOLVE trialSTRIVE trialBaseline characteristicsMigraine daysIndirect comparisonSmall-molecule calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistLong-term preventive effectsAnti-CGRP monoclonal antibodiesMean differencePlacebo-controlled trialPeptide receptor antagonistSingle-arm trialTreatment of migraineVersion 2 scoreMigraine-Specific QualityAssessment test scoreAcute treatmentRandomized trialsWeek 12HRQoL dataReceptor antagonist
2020
Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP Monoclonal Antibodies (mAb) Examining Health-related Quality of Life (HRQoL). (1951)
Popoff E, Johnston K, Harris L, Thiry A, Croop R, Coric V, L’Italien G. Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP Monoclonal Antibodies (mAb) Examining Health-related Quality of Life (HRQoL). (1951). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1951.Peer-Reviewed Original ResearchAnti-CGRP monoclonal antibodiesMatching-adjusted indirect comparisonHealth-related qualityVersus PlaceboIndirect comparisonMonoclonal antibodiesPlaceboAntibodiesMatching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP-targeted Monoclonal Antibodies Examining Monthly Migraine Days in the Treatment of Migraine (4563)
Popoff E, Johnston K, Croop R, Thiry A, Harris L, Coric V, L’Italien G. Matching-adjusted Indirect Comparisons of Intermittent Oral Rimegepant Versus Placebo and Injectable anti-CGRP-targeted Monoclonal Antibodies Examining Monthly Migraine Days in the Treatment of Migraine (4563). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4563.Peer-Reviewed Original ResearchMatching-adjusted indirect comparisonMonthly migraine daysTreatment of migraineVersus PlaceboMigraine daysIndirect comparisonMonoclonal antibodiesPlacebo